Skip to content
Menu
INFECTIOUS ECONOMICS | by Blythe Adamson
  • Methods
    • Research
    • Course
  • Publications
    • Manuscripts
    • Abstracts
    • Other Articles
  • Teaching
  • Press
  • About
INFECTIOUS ECONOMICS | by Blythe Adamson
October 25, 2018January 31, 2019

data|evidence|policy|practice

The global demand from hospitals for real-world evidence is rapidly increasing. Yet, decision-makers outside the United States are frequently challenged by the assumption of transferability of data and evidence from one county to another. Conversations with Gary O’Brien and colleagues at an Irish hospital, university, and government health authority sparked the idea to write-up a case-study with lessons learned so far. 

TL;DR :  data –> evidence –> policy –> (slow/hard) –> practice

#for data scientists that like to keep things tidy

clinical_practice <- data %>%
     GenerateEvidence(hard_work) %>%
          inner_join(policy, by = safety, cost_effectiveness) %>%
               mutate(utilization = ifelse(time, change, no_change))
The case-study paints an interesting portrait of how new cancer evidence informed European regulatory decisions biosimilar drugs and then trickled down to slowly change clinical practice in Ireland. The Irish Department of Health (DoH) is in the process of developing a new national biosimilar medicines policy. They aim to increase biosimilar use by creating a robust framework where biologicals and biosimilars can be used safely, cost-effectively, and confidently in the health service.

Key Points:

    • There was a significant time lag between regulatory approval and clinical acceptance of biosimilar infliximab CT-P13 in Ireland.
    • In this example from an Irish teaching hospital, the introduction of the biosimilar first to new patients, along with a switching study executed in parallel, helped to raise prescriber confidence.
  • Increased biosimilar medicine usage is of benefit to all stakeholders including patients, prescribers, healthcare payers, and manufacturers.

Irish Biosimilar Policy Topics

Read the full story in this issue of Value and Outcomes Spotlight. 

Reference

O’Brien G, Mulcahy M, Byrne S, Carroll D, Courtney G, Walshe V, Adamson B. Biosimilar Adoption and Acceptance in Ireland—Still More to Be Done. Value & Outcomes Spotlight. 2018 Jul; 4(4):29-31.

TL;DR means “too long; didn’t read”

Disclosure: I am a full-time employee at Flatiron Health, a health tech company in New York City that is an independent subsidiary of Roche. The views expressed here are my own and do not represent the official position of Flatiron Health or Roche.

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)

Related

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Top Posts & Pages

  • About
    About
  • Course
    Course
  • Major League Sports Lessons in COVID-19
    Major League Sports Lessons in COVID-19
  • Research
    Research
  • Manuscripts
    Manuscripts
  • CHEAT SHEET: Cancer Immunotherapy
    CHEAT SHEET: Cancer Immunotherapy
  • Causal Inference Book Club
    Causal Inference Book Club
My Tweets
Twitter
©2021 INFECTIOUS ECONOMICS | by Blythe Adamson | Powered by WordPress and Superb Themes!